Increased interest in the underlying pathogenesis of primary lateral sclerosis (PLS) and its
relationship to amyotrophic lateral sclerosis (ALS) has corresponded to a growing number of …

Purpose The objective of this review was to explore the potential clinical application of
unconventional non-amino acid PET radiopharmaceuticals in patients with gliomas …

Purpose To investigate the whole-brain landscape of iron-related abnormalities in
amyotrophic lateral sclerosis (ALS) by using the in vivo MRI technique of quantitative …

Objectives Positron emission tomography (PET) and volume of interest (VOI) analysis have
recently shown in amyotrophic lateral sclerosis (ALS) an accuracy of 93% in differentiating …

An objective biomarker for early identification and accurate differential diagnosis of
amyotrophic lateral sclerosis (ALS) is lacking. 18F-FDG PET brain imaging with advanced …

Amyotrophic lateral sclerosis (ALS) is a neurological disease characterized by the
progressive loss of cortical, bulbar, and spinal motor neurons (MNs). The cardinal …

Abstract Objective: 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography
(PET) single-center studies using support vector machine (SVM) approach to differentiate …

Single time point positron emission tomography (PET) studies of patients with amyotrophic
lateral sclerosis and frontotemporal dementia (ALS-FTD), have demonstrated …

Aim Patients with idiopathic normal-pressure hydrocephalus (iNPH) can show a global
reduction in cerebral glucose metabolism at [18 F] Fluorodeoxyglucose (FDG) PET. The …

Introduction Amyotrophic lateral sclerosis (ALS) is a neurodegenerative, multisystem
disorder. Its clinical presentation typically consists of progressive focal muscle atrophy and …